.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX11_Quizartinib.Quizartinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX11_Quizartinib.Quizartinib| name: | Quizartinib |
| ATC code: | L01EX11 | route: | oral |
| n-compartments | 2 |
Quizartinib is an oral, selective type II FLT3 inhibitor used in the treatment of acute myeloid leukemia (AML) with FLT3-ITD mutations. It is approved for use in adult patients and has demonstrated efficacy in relapsed or refractory AML.
Pharmacokinetic parameters observed in adult patients with relapsed/refractory AML; population-PK model with a two-compartment structure following oral administration.
Kang, D, et al., & Yin, O (2020). Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia. Journal of clinical pharmacology 60(12) 1629–1641. DOI:10.1002/jcph.1680 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32598495
Usuki, K, et al., & Sakajiri, S (2019). Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. International journal of hematology 110(6) 654–664. DOI:10.1007/s12185-019-02709-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31359361